Drug Type Biosimilar, Monoclonal antibody |
Synonyms Ustekinumab Biosimilar (Ivy Pharma, Inc.), IVY-1007 |
Target |
Action inhibitors |
Mechanism IL-12p40 inhibitors(Interleukin-12 subunit beta inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colitis, Ulcerative | Preclinical | United States | 01 Nov 2024 | |
| Crohn Disease | Preclinical | United States | 01 Nov 2024 | |
| Psoriasis | Preclinical | United States | 01 Nov 2024 |






